Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Changes in second-line lymphoma treatment

Alison Moskowitz • 2 Jun 2019
ASCO 2019
Lymphoma Rituximab

Alison Moskowitz, MD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the standard approach to relapsed/refractory lymphoma and the increased use of novel agents such as rituximab and checkpoint inhibitors in second-line therapy. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Alison Moskowitz

2:50
Less aggressive approaches in relapsed/refractory Hodgkin lymphoma
Alison Moskowitz • 19 Mar 2021
5:01
Relapsed & refractory classic Hodgkin lymphoma
Alison Moskowitz • 19 Mar 2021
1:40
Personalized approaches to Hodgkin lymphoma
Alison Moskowitz • 19 Mar 2021
2:36
Angioimmunoblastic T-cell lymphoma treatment
Alison Moskowitz • 2 Jun 2019

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals